INCY Upcoming Earnings (Q3 2023)
|Earnings Date:||Oct 30, 2023|
Current P/E* ratio: 35.79 | Price (Sep 25, 2023, EOD): $58.75
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for INCY Premium
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chr... INCY Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.